Literature DB >> 30123541

Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?

Anthonie J van der Wekken1, Klaas Kok2, Harry J M Groen1.   

Abstract

Entities:  

Year:  2018        PMID： 30123541      PMCID： PMC6072953          DOI： 10.21037/jtd.2018.06.45

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  10 in total

1.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Authors:  Shirish M Gadgeel; Leena Gandhi; Gregory J Riely; Alberto A Chiappori; Howard L West; Michele C Azada; Peter N Morcos; Ruey-Min Lee; Linta Garcia; Li Yu; Frederic Boisserie; Laura Di Laurenzio; Sophie Golding; Jotaro Sato; Shumpei Yokoyama; Tomohiro Tanaka; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2014-08-18       Impact factor: 41.316

2.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer.

Authors:  A J van der Wekken; R Pelgrim; N 't Hart; N Werner; M F Mastik; L Hendriks; E H F M van der Heijden; M Looijen-Salamon; A J de Langen; J Staal-van den Brekel; S Riemersma; B E van den Borne; E J M Speel; A-M C Dingemans; T J N Hiltermann; A van den Berg; W Timens; E Schuuring; H J M Groen
Journal:  Clin Cancer Res       Date:  2017-02-09       Impact factor: 12.531

4.  Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

Authors:  Toyoaki Hida; Hiroshi Nokihara; Masashi Kondo; Young Hak Kim; Koichi Azuma; Takashi Seto; Yuichi Takiguchi; Makoto Nishio; Hiroshige Yoshioka; Fumio Imamura; Katsuyuki Hotta; Satoshi Watanabe; Koichi Goto; Miyako Satouchi; Toshiyuki Kozuki; Takehito Shukuya; Kazuhiko Nakagawa; Tetsuya Mitsudomi; Nobuyuki Yamamoto; Takashi Asakawa; Ryoichi Asabe; Tomohiro Tanaka; Tomohide Tamura
Journal:  Lancet       Date:  2017-05-10       Impact factor: 79.321

Review 5.  The next-generation ALK inhibitors.

Authors:  Georg Pall
Journal:  Curr Opin Oncol       Date:  2015-03       Impact factor: 3.645

6.  The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Authors:  Luc Friboulet; Nanxin Li; Ryohei Katayama; Christian C Lee; Justin F Gainor; Adam S Crystal; Pierre-Yves Michellys; Mark M Awad; Noriko Yanagitani; Sungjoon Kim; AnneMarie C Pferdekamper; Jie Li; Shailaja Kasibhatla; Frank Sun; Xiuying Sun; Su Hua; Peter McNamara; Sidra Mahmood; Elizabeth L Lockerman; Naoya Fujita; Makoto Nishio; Jennifer L Harris; Alice T Shaw; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2014-03-27       Impact factor: 39.397

7.  Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Authors:  Ted W Johnson; Jeffrey A Engelman; Alice T Shaw; Luc Friboulet; Ignaty Leshchiner; Justin F Gainor; Simon Bergqvist; Alexei Brooun; Benjamin J Burke; Ya-Li Deng; Wei Liu; Leila Dardaei; Rosa L Frias; Kate R Schultz; Jennifer Logan; Leonard P James; Tod Smeal; Sergei Timofeevski; Ryohei Katayama; A John Iafrate; Long Le; Michele McTigue; Gad Getz
Journal:  N Engl J Med       Date:  2015-12-23       Impact factor: 91.245

8.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

9.  Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Shirish M Gadgeel; Alice T Shaw; Ramaswamy Govindan; Leena Gandhi; Mark A Socinski; D Ross Camidge; Luigi De Petris; Dong-Wan Kim; Alberto Chiappori; Denis L Moro-Sibilot; Michael Duruisseaux; Lucio Crino; Tommaso De Pas; Eric Dansin; Antje Tessmer; James Chih-Hsin Yang; Ji-Youn Han; Walter Bordogna; Sophie Golding; Ali Zeaiter; Sai-Hong Ignatius Ou
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

10.  The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.

Authors:  Sen Zhang; Rana Anjum; Rachel Squillace; Sara Nadworny; Tianjun Zhou; Jeff Keats; Yaoyu Ning; Scott D Wardwell; David Miller; Youngchul Song; Lindsey Eichinger; Lauren Moran; Wei-Sheng Huang; Shuangying Liu; Dong Zou; Yihan Wang; Qurish Mohemmad; Hyun Gyung Jang; Emily Ye; Narayana Narasimhan; Frank Wang; Juan Miret; Xiaotian Zhu; Tim Clackson; David Dalgarno; William C Shakespeare; Victor M Rivera
Journal:  Clin Cancer Res       Date:  2016-10-25       Impact factor: 12.531
  10 in total
  1 in total

1.  Targeted RNA-sequencing assays: a step forward compared to FISH and IHC techniques?

Authors:  Gaëlle Tachon; Ulrich Cortes; Sophie Richard; Sébastien Martin; Serge Milin; Camille Evrard; Corinne Lamour; Lucie Karayan-Tapon
Journal:  Cancer Med       Date:  2019-10-25       Impact factor: 4.452
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.